×

Kybella

To schedule an appointment

Call Us

(470) 769-9400
We see 3 images. A Before,  a mid treatment and an after images on the profile of a man. We can see gradual improvements in the later two images. In the after image the drooping double chine has been dramatically reduced. The man's jawline is well defined in the after images We see 3 images. A Before,  a mid treatment and an after images on a 3/4 angle of a man. We can see gradual improvements in the later two images. In the after image the drooping double chine has been dramatically reduced. The man's jawline is well defined in the after images We see 3 images. A Before, a mid treatment and an after images on the profile of a woman. We can see  gradual improvements in the later two images. In the after image the drooping double chine has been dramatically reduced. The woman's jawline is well defined in the after images We see 3 images. A Before, a mid treatment and an after images on the3/4 angle of a woman's profile . We can see  gradual improvements in the later two images. In the after image the drooping double chine has been dramatically reduced. The woman's jawline is well defined in the after images

Indications, Important Safety Information and Prescribing Information

Toggle

All images © 2020 Allergan

KYBELLA®


KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information

INDICATION

KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

KYBELLA® is contraindicated in the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS

Marginal Mandibular Nerve Injury

Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia

Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising

In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting into or in Proximity to Vulnerable Anatomic Structures

To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles. Care should be taken to avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury

Injection Site Alopecia

Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration and Necrosis

Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

ADVERSE REACTIONS

The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see KYBELLA® full Prescribing Information.

Say goodbye to your double chin.


THE KYBELLA DIFFERENCE


Want a nonsurgical double chin removal treatment that permanently removes fat cells and pockets from under your chin? Interested in the first and only FDA approved injectable treatment? Then Kybella is the answer!



KYBELLA AT A GLANCE


Genetics, aging, and weight gain all play a role in the development of a double chin, and diet and exercise don’t always help. At Springs Dermatology MD, we use Kybella to eliminate the excess fat in the submental area which causes a double chin and aesthetically impacts your profile. The result? No more double chin!



THE TREATMENT DIFFERENCE


Naturally occurring Deoxycholic acid is the active ingredient that makes Kybella work so well. It actively breaks down fat in your body. While you might need multiple treatments, our experienced dermatologists ensure the treatments are quick, precise and result in minimal discomfort. At Springs Dermatology MD, our professionalism and focus on personal care mean we take the time to discuss all the risks and benefits with you to properly assess your needs so that you get the best Kybella results in Sandy Springs and Metro Atlanta.


We can even combine Kybella with NovaThreads for a chin lift and neck lift.


For more information: https://www.mykybella.com/


What is submental fullness?

Submental fullness is a gathering of excess fat beneath the chin, commonly known as “double chin.” It can be something you’ve had your whole life due to genetics or start to appear as you get older or if you gain weight.


What is KYBELLA®?

The active ingredient in KYBELLA® is synthetic deoxycholic acid. Deoxycholic acid is a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into the fat beneath the chin, KYBELLA® destroys fat cells and once destroyed, these cells can no longer store or accumulate fat. This results in a noticeable reduction in fullness under the chin, revealing an improved chin profile.


When will I see the results?

Visible results in 2-4 treatments. The results of KYBELLA® injections happen gradually. You will start noticing changes in your appearance within 4 to 6 weeks. However, it typically takes about 3 months before you can see the full results.


How long do the results last?

The results are permanent. Once dissolved, these cells can no longer store or accumulate fat, so further treatment is not expected once you reach your desired aesthetic goal.


How many treatments will I need?

Since everyone’s chin profile is different, the number of treatments varies from patient to patient.

 

Does it hurt?

Each patient will have their own pain threshold. Patients have reported that KYBELLA®  injections are no more than a mild burning sensation for around 15 minutes. We apply ice packs for this time to maximize our patients' comfort.

 

What is the downtime?

After KYBELLA® treatment, you will likely have some swelling, bruising, or numbness under your chin that will subside within 2 to 3 days. Cold compresses may be used to reduce the swelling.


Is KYBELLA® safe?

KYBELLA® is a prescription medicine and is the only FDA-approved injectable treatment used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called “double chin.”



We see 3 images. A Before,  a mid treatment and an after images on the profile of a man. We can see gradual improvements in the later two images. In the after image the drooping double chine has been dramatically reduced. The man's jawline is well defined in the after images We see 3 images. A Before,  a mid treatment and an after images on a 3/4 angle of a man. We can see gradual improvements in the later two images. In the after image the drooping double chine has been dramatically reduced. The man's jawline is well defined in the after images We see 3 images. A Before, a mid treatment and an after images on the profile of a woman. We can see  gradual improvements in the later two images. In the after image the drooping double chine has been dramatically reduced. The woman's jawline is well defined in the after images We see 3 images. A Before, a mid treatment and an after images on the3/4 angle of a woman's profile . We can see  gradual improvements in the later two images. In the after image the drooping double chine has been dramatically reduced. The woman's jawline is well defined in the after images

Indications, Important Safety Information and Prescribing Information

Toggle

All images © 2020 Allergan

KYBELLA®


KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information

INDICATION

KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

KYBELLA® is contraindicated in the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS

Marginal Mandibular Nerve Injury

Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia

Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising

In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting into or in Proximity to Vulnerable Anatomic Structures

To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles. Care should be taken to avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury

Injection Site Alopecia

Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration and Necrosis

Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

ADVERSE REACTIONS

The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see KYBELLA® full Prescribing Information.

Call us to schedule an appointment

JOIN OUR MAILING LIST

×

Thank you for signing up.

Send

Call Us Call (470) 769-9400